NRF2 Review Article Published by Kuria Therapeutics in Current Opinion in Pharmacology

- Article by Kuria's Chief Executive Officer Dr. Keith Ward summarizes role of NRF2 pathway in corneal endothelial dysfunction

Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, is pleased to announce the publication of a review article summarizing the relevance of NRF2 activation in corneal endothelial disease.

Authored by Kuria's Chief Executive Officer, Dr. Keith Ward, this invited review article entitled "Targeting the NRF2 Pathway: A Promising Approach for Corneal Endothelial Dysfunction" was published in Current Opinion in Pharmacology 74:102429 (2024). Open access to this publication is available until 21 Feb 2024 at this link.

The abstract of the published review article is as follows:

Maintaining corneal endothelial function is required for vision, and corneal endothelial dysfunction is a major cause of visual deficits and blindness worldwide. To date there has been a dearth of innovation for therapeutics targeting the corneal endothelium. However, recent advances in understanding the role of oxidative stress and mitochondrial dysfunction have revealed potential avenues for the development of new therapies. This review summarizes recent developments in elucidating the role of the NRF2 pathway in corneal endothelial health and disease, focusing specifically on Fuchs’ endothelial corneal dystrophy and the loss of corneal endothelial cells associated with cataract surgery. The pro-mitochondrial and antioxidant phenotype elicited by NRF2 activation offers a promising opportunity for new therapeutics for the diseased corneal endothelium.

Theoretical curves illustrating the effect of loss of corneal endothelial cells following an acute insult such as cataract surgery (ECD: endothelial cell density). Slope data in this image were modeled from Armitage et al. 2003.

About Kuria Therapeutics, Inc.:

Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com. 

Contacts

Investor Relations and Media 

Kuria Therapeutics: 

Corporate Communication 

info@kuriatx.com